Welcome to Sott.net
Sun, 17 Dec 2017
The World for People who Think

Health & Wellness


Combining antibody immunotherapy treatments could improve lymphoma survival

Combining two different immunotherapy treatments could dramatically improve lymphoma survival, according to a Cancer Research UK funded study published in Cancer Cell today (Thursday).

Researchers from the University of Southampton tested different combinations of antibodies* in the lab to see how they interact with each other and what effect this has on how the immune system fights cancer.

They found one combination - anti-CD27 and anti-CD20 - greatly increased life expectancy in mice with cancer. While most of the mice given just one of the antibodies died within 80 days, nearly all mice given both antibodies survived beyond 100 days.**

When combined, the researchers found the antibodies recruit greater numbers of immune cells called myeloid cells, as well as increasing their ability to destroy cancer cells.


Increase in prevalence of developmental disabilities in US kids

boy with blocks
The prevalence of children diagnosed with any developmental disability increased significantly in recent years, from 5.76% in 2014 to 6.99% in 2016, according to new data from the National Center for Health Statistics (NCHS) at the Centers for Disease Control and Prevention.

This increase was largely the result of an increase in the prevalence of children diagnosed with a developmental delay other than autism spectrum disorder (ASD) or intellectual disability, a rise from 3.57% in 2014 to 4.55% in 2016.

Comment: Alarming results of Big Pharma & the CDC in America: 1 in 6 children now has a developmental disability


Metabolic therapy for the prevention and treatment of chronic disease

Cancer has become Americans' No. 1 health concern. According to the American Cancer Society, more than 1,600 people die every day from cancer in the U.S. That's over 600,000 people each year. When you include the entire world population that number climbs tenfold to over 7.6 million. Statistics suggest half of all men and 4 out of 10 women will develop cancer during their lifetimes.

Alzheimer's disease is another major health threat that has dramatically increased in recent years. Between 1999 and 2014, the death rate from Alzheimer's increased by 55 percent. According to the latest statistics, Alzheimer's claims the lives of more than half a million Americans each year, and unless there are radical changes, many experts project half of the population will eventually develop it.

These are grim statistics, but there is hope. Mounting evidence shows both of these conditions - as well as many other top killers - are metabolic diseases. This is actually good news, because that means you can prevent, treat and recover from them like other metabolic conditions, such as Type 2 diabetes and heart disease.


Monsanto's Roundup causes antibiotic resistance - a fact that's not considered by regulators

© greenmedinfo.com
Antimicrobial resistance could cause up to 10 million deaths every year.

Both the active and inert ingredients in common herbicides induce antibiotic resistance in human pathogenic bacteria, according to the latest research from New Zealand scientists, published in Microbiology this week. Previous research from the same team found in 2015 that commercial formulations of Roundup (containing glyphosate and inert ingredients) and Kamba (containing 2,4-D, Dicamba, and inert ingredients) caused antibiotic resistance to develop in Salmonella eterica andEscherichia coli, but this new research drills down into what ingredients in these formulations resulted in the effect. Lead author of the study, Jack Heinemann, PhD, University Canterbury's School of Biological Sciences, explains that ultimately this research indicates that, "The sub-lethal effects of industrially manufactured chemical products should be considered by regulators when deciding whether the products are safe for their intended use,"

Comment: Learn more about the growing concerns over antibiotic resistance: The following article is a must read: Dr. Brad Spellberg: Antibiotic resistance is "Everyone's Fault"
Dr. Brad Spellberg is an infectious disease specialist and leader in the field of developing ways to combat drug resistant infections. Spellberg, who wrote a book about the problem, Rising Plague, told FRONTLINE that the science of developing new tools in the fight against infection is in trouble, unless the culture around developing drugs changes.


Scientists seek new strategies to fight MS

nerve cells
Taking narrow aim at the immune system isn’t enough, so researchers are looking for new treatment targets within nerve cells and even in the gut.
James Davis used to be an avid outdoorsman. He surfed, hiked, skateboarded and rock climbed. Today, the 48-year-old from Albuquerque barely gets out of bed. He has the most severe form of multiple sclerosis, known as primary progressive MS, a worsening disease that destroys the central nervous system. Diagnosed in May 2011, Davis relied on a wheelchair within six months. He can no longer get up to go to the bathroom or grab a snack from the fridge.

Davis hoped life might improve when he was chosen in 2012 to participate in a clinical trial of a drug called ocrelizumab. The drug offered a first sliver of hope for patients waiting for a cure, or at least something to slow down the disease's staggering march. Early research suggested the drug could help some of the roughly 60,000 people in the United States, like Davis, suffering from primary progressive MS. The drug also held promise for patients with the other major form of the disease, relapsing-remitting MS, which afflicts about 340,000 people nationwide.

For some people, ocrelizumab seemed to work. Brain scans of patients with primary progressive MS showed fewer signs of damage and the patients' ability to walk deteriorated more slowly than in individuals who received a placebo, researchers reported in January in the New England Journal of Medicine. The drug also helped people with relapsing-remitting MS, which, as the name implies, includes shifts between disability and wellness. Over a year's time, these patients experienced about half as many flare-ups as those taking another commonly prescribed drug, a different research group reported in the same issue of the journal.

Comment: How about trying some old strategies like diet, sunlight and CBD oil?


Epigenetic therapy drug combination may boost immunotherapy responses in lung cancer patients

Epithelial Cell
© Michael Topper and Michelle Vaz
Johns Hopkins Kimmel Cancer Center researchers and colleagues have identified a novel drug combination therapy that could prime nonsmall cell lung cancers to respond better to immunotherapy. These so-called epigenetic therapy drugs, used together, achieved robust anti-tumor responses in human cancer cell lines and mice.

During the study, published Nov. 30, 2017, in the journal Cell, a team of researchers led by graduate student Michael Topper; research associate Michelle Vaz, Ph.D.; and senior author Stephen B. Baylin, M.D., combined a demethylating drug called 5-azacytidine that chemically reignites some cancer suppressor genes' ability to operate, with one of three histone deacetylase inhibitor drugs (HDACis). The HDACis work against proteins called histone deacetylases that are involved in processes, such as cell copying and division, and can contribute to cancer development. The combination therapy triggered a chemical cascade that increased the attraction of immune cells to fight tumors and diminished the work of the cancer gene MYC. Based on these findings, investigators have launched a clinical trial of the combination therapy in patients with advanced, nonsmall cell lung cancer.

The development of therapeutic approaches for patients with lung cancer has been a critical medical need, says Baylin, the Virginia and Daniel K. Ludwig Professor of Cancer Research at the Kimmel Cancer Center. While immune checkpoint therapy has been "a tremendous step forward, less than half of patients with lung cancer have benefited to date," he says.

Comment: See also:


Wait, did the mainstream media just say, "Shady vaccine trial"?

oral polio vaccine

While the mainstream media howls about Peter Thiel's herpes vaccine investment, FDA-approved vaccine trials use poor black babies as test subjects, thumbprints for 'consent' and hide negative results

It is very rare for the mainstream media to critically report on questionable activity by the pharmaceutical industry and especially by vaccine manufacturers, so the recent rash of news stories about a "shady" and "patently unethical" offshore vaccine trial funded by billionaire entrepreneur Peter Thiel is intriguing.

Twenty patients on the quiet Caribbean island of St. Kitts were reportedly given an experimental genital herpes virus vaccine by a small private vaccine manufacturing company called Rational Vaccines in 2016.


Indiana Attorney General declares CBD oil illegal, even though its non-psychoactive

In the latest from the feckless battle of the inane known as the U.S. government's War on Drugs, Indiana Attorney General Curtis Hill deemed CBD oil - a cannabis-derived substance renowned for the treatment of multiple ailments, including childhood epilepsy, but without the psychoactive effects of THC - illegal.

To families of loved ones, and particularly children, with intractable epilepsy, severe and chronic pain, serious anxiety, or a bevy of other issues, the declaration of CBD as illegal not only poses potential health complications in the future, but lacks the backing of science - as myriad studies show promise nearly in line with anecdotal accounts of miraculous healing benefits found in CBD.

Comment: The Health & Wellness Show: The Highs and Lows of Cannabis as Medicine

Life Preserver

Niacin treatment of schizophrenia - Recent research supports Abram Hoffer's original work

brain schizophrenia
© Alan Ajifo (Creative Commons)
Schizophrenia is a devastating and complex disease that can include a variety of specific clinical conditions. Drugs to treat schizophrenia have not advanced much beyond the 1960s; in many cases they are not very effective, and they have severe side-effects. The problem is that the cause of schizophrenia is unknown, and precisely how the drugs affect brain circuitry is also unknown. Schizophrenia is thought to have a substantial environmental component (toxins, culture, upbringing, lifestyle, diet, etc.), but its onset is likely to be predisposed by genetic factors.[1] Genetic analysis has recently made great progress in identifying genes that cause diseases. Many diseases that strike young adults, as schizophrenia often does, have been shown to be caused by one or just a few specific mutations. For example, some diseases that cause blindness are now known to be caused by a mutation in one or more of the genes that code for molecules in the brain essential for sight. In one recent case, gene therapy approved by the FDA to correct the mutation has restored sight in blind people. [2]

Pessimism about schizophrenia

However, research into the possible genetic cause of schizophrenia has not found any obvious candidate gene mutations. Part of the problem is that schizophrenia is not just one disease; it comprises a family of interrelated conditions and is diagnosed by several criteria, which implies that a variety of causes may contribute. Apparently, many gene mutations may contribute to schizophrenia, but none yet found have an influence strong enough to be the exclusive cause.

Comment: See also: Niacin and schizophrenia


Mothers must breastfeed for at least 2 months to decrease risk of SIDS

Mother holding baby
© Jonathan Ernst / Reuters
Just two months of breastfeeding may be enough to cut the risk of your child dying from SIDS (sudden infant death syndrome), according to AAP News. A study looked retrospectively at eight other studies involving SIDS cases and compared them to a control group, and found that breastfeeding must continue at least two months to be protective. Researchers said they weren't sure what it is about breast-feeding that has the positive effect, but that it may have something to do with breast milk's impact on immune systems and early brain development.

There's no question breast milk is a perfect food for the human infant as it contains all the nutrients vital for healthy growth and development, plus beneficial microbes that promote a healthy gut microbiome. Breastfeeding also has some amazing benefits for moms, and it's these dual benefits for both mom and baby that lead me to encourage you to do all you can to breastfeed your baby successfully, and exclusively, for at least the first six months; and longer if possible.

You should begin nursing as soon after birth as possible, as your baby's sucking instinct will be very strong at that time, giving you the best chance of success. Newborns need to nurse at least once every two hours, for about 15 minutes or so on each side, but most do not adhere to any kind of strict schedule and feedings can vary in length. It is this frequent nursing that stimulates your breasts to produce increasing amounts of milk to keep up with demand. It's natural, and it's what's best for you and baby.

Comment: They also argue with the absurd claim that it is "unethical".